Targeted Medical Pharma, Inc. (TRGM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTargeted Medical Pharma, Inc. (TRGM) trades at $0.00001. Targeted Medical Pharma, Inc. (TRGM) is a specialized pharmaceutical company focused on developing amino acid-based medications. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for TRGM: TRGM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Targeted Medical Pharma, Inc. (TRGM) Healthcare & Pipeline Overview
Targeted Medical Pharma, Inc. specializes in amino acid-based medications, offering a diverse portfolio of patented products and proprietary services aimed at addressing a wide range of health conditions, primarily in the U.S. market.
What Is the Investment Thesis for TRGM?
Targeted Medical Pharma, Inc. presents a unique investment thesis driven by its specialized portfolio of amino acid-based medications, which cater to a diverse range of health conditions. The company operates in a niche market with significant growth potential, particularly in addressing metabolic and psychological health issues. With a gross margin of 60.2%, Targeted Medical Pharma demonstrates strong profitability potential despite a current profit margin of -57.9%. The proprietary PDRx billing system adds a competitive edge by streamlining physician dispensing processes, potentially increasing market penetration. However, the company faces ongoing financial challenges, as indicated by its low market capitalization and negative profit margins. Investors should monitor the company's efforts to stabilize its financial position and expand its product offerings, which could serve as key growth catalysts in the coming years.
Based on FMP financials and quantitative analysis
TRGM Key Highlights
Market Cap: $0.00B, indicating a minimal market presence and potential volatility.
- Profit Margin: -57.9%, reflecting current financial challenges.
- Gross Margin: 60.2%, showcasing strong potential for profitability.
- Beta: -0.45, indicating lower volatility compared to the broader market.
- Employees: 30, a small but specialized workforce focused on niche pharmaceutical development.
Who Are TRGM's Competitors?
TRGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AMGN Amgen Inc. | $403.04 | -1.04% | $218B | 84 5-pillar |
| GILD Gilead Sciences, Inc. | $144.74 | -1.87% | $179B | 65 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | 97 5-pillar |
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRGM's Key Strengths?
Strong gross margin of 60.2%, indicating potential profitability.
- Specialized product offerings targeting niche health conditions.
- Proprietary technology that enhances operational efficiency.
What Are TRGM's Weaknesses?
Negative profit margin of -57.9%, indicating financial instability.
- Limited market capitalization, suggesting low investor confidence.
- Small workforce may limit scalability and operational capacity.
What Are the Key Risks for TRGM?
Financial-distress signal — its Altman Z-Score of -24.53 sits in the distress zone (elevated bankruptcy risk).
- Regulatory challenges that could delay product approvals.
- Financial instability reflected in negative profit margins.
- Intense competition from larger pharmaceutical companies.
What Threats Does TRGM Face?
- Intense competition from larger pharmaceutical companies.
- Regulatory challenges in drug approval processes.
- Market volatility impacting investor sentiment and funding opportunities.
What Are TRGM's Competitive Advantages?
- Specialized knowledge in amino acid-based therapies.
- Proprietary PDRx billing system enhancing operational efficiency.
- Established relationships with healthcare providers and pharmacies.
What Does TRGM Do?
Targeted Medical Pharma, Inc., operating under the name Physician Therapeutics, was founded in 1996 and is headquartered in Los Angeles, California. Initially established as Targeted Medical Foods, the company rebranded in 2006 to reflect its broader focus on pharmaceutical products. Targeted Medical Pharma is dedicated to the development and marketing of amino acid-based medications, which are designed to address a variety of health conditions including metabolic syndrome, obesity, anxiety-related sleep disturbances, hypertension, viral infections, cognitive impairments, and various pain disorders. The company’s product offerings include specialized medical food products, dietary supplements, and generic drugs. A notable aspect of its business model is the proprietary billing system and software known as PDRx, which supports physician dispensing, inventory management, and regulatory reporting. This system enhances the efficiency of healthcare providers by managing invoicing and payment collection for products dispensed by physicians. Distribution of Targeted Medical Pharma's products is facilitated through a combination of external distributors and an in-house sales team, which directly engages with physician clients. With a workforce of 30 employees, the company is positioned to leverage its specialized knowledge in amino acid therapies to meet the growing demand for innovative healthcare solutions.
What Products and Services Does TRGM Offer?
- Develop and market amino acid-based medications.
- Offer a range of patented medical food products and dietary supplements.
- Provide generic drugs targeting various health conditions.
- Facilitate physician dispensing through the proprietary PDRx billing system.
- Manage invoicing and payment collection for dispensing physician clients.
- Engage with healthcare providers through an in-house sales team.
How Does TRGM Make Money?
- Generate revenue through the sale of patented and generic pharmaceutical products.
- Offer proprietary billing and inventory management software to healthcare providers.
- Provide invoicing and payment collection services to physicians dispensing medications.
- Utilize a network of external distributors alongside an in-house sales team for product distribution.
What Industry Does TRGM Operate In?
The pharmaceutical industry, particularly the specialty and generic drug sector, is experiencing significant growth driven by increasing healthcare demands and advancements in drug development. With a projected annual growth rate of approximately 7.5%, the market is expanding due to rising prevalence of chronic diseases and an aging population. Targeted Medical Pharma, Inc. operates within this dynamic landscape, focusing on amino acid-based therapies that cater to specific health conditions. The competitive landscape includes both established pharmaceutical giants and emerging biotech firms, positioning Targeted Medical Pharma as a niche player with specialized offerings that address unmet medical needs.
Who Are TRGM's Key Customers?
- Healthcare providers, including physicians and clinics.
- Pharmacies dispensing the company's products.
- Patients requiring specialized amino acid-based medications.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Targeted Medical Pharma, Inc. operates in the Healthcare sector. It is headquartered in Los Angeles, US. TRGM has traded publicly since 2012.
Insider Activity
7 transactions · 0 purchases, 0 sales, 7 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Targeted Medical Pharma, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -24.53 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Targeted Medical Pharma, Inc. stands at 26.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
TRGM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
TRGM Latest News
No recent news available for TRGM.
TRGM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TRGM.
Price Targets
Wall Street price target analysis for TRGM.
TRGM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TRGM; grades run from A+ (80-100) to F (below 30).
Leadership: Kim Giffoni
CEO
Kim Giffoni has been at the helm of Targeted Medical Pharma, Inc. since its rebranding in 2006. With a strong background in pharmaceutical management and business development, she has played a crucial role in steering the company through various market challenges. Giffoni holds a degree in pharmaceutical sciences and has extensive experience in the healthcare sector, focusing on innovative product development and strategic partnerships.
Track Record: Under Kim Giffoni's leadership, Targeted Medical Pharma has expanded its product portfolio and enhanced its operational capabilities through the introduction of the PDRx billing system. Her strategic vision has been pivotal in navigating the company through a competitive landscape, aiming to solidify its market position.
TRGM OTC Market Information
The OTC Other tier is a classification for stocks that do not meet the requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have less stringent reporting requirements, leading to less transparency and potentially higher risk for investors compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited regulatory oversight compared to stocks listed on major exchanges.
- Potential for high volatility due to low trading volume.
- Increased risk of fraud or mismanagement in less regulated environments.
- Review the company's financial filings for the last three years.
- Assess the management team's experience and track record.
- Evaluate the competitive landscape and market position.
- Investigate any pending regulatory approvals for products.
- Monitor news and updates related to the company's operations.
- Established history since 1996, indicating longevity in the market.
- Proprietary technology (PDRx) that supports operational efficiency.
- Existing product portfolio with approved medications.
TRGM Healthcare Stock FAQ
What are the key growth opportunities for TRGM in healthcare?
Targeted Medical Pharma, Inc. has several growth opportunities, including expansion into new therapeutic areas such as metabolic syndrome treatments, which is projected to reach a $20 billion market by 2027. The company can also explore geographic expansion beyond the U.S. market, where the global pharmaceutical market is expected to grow at a CAGR of 5.8% through 2025.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to OTC classification and may not reflect the full picture of the company's health.